IMforte: Maintenance Lurbinectedin + Atezolizumab Significantly Improves OS and PFS in ES-SCLC

ASCO Daily News·Jun 2

This story is reported by ASCO Daily News. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

FDA Approves Lurbinectedin Plus Atezolizumab as First-Line Maintenance Therapy for ES-SCLC

OncLive·Oct 2

2

Maintenance Therapy With Lurbinectedin Plus Atezolizumab Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer

The ASCO Post·Jun 10

3

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

AJMC·May 22

4

- European Medical Journal ES-SCLC Maintenance Outcomes From IMforte Trial: ASCO 2025 - AMJ

European Medical Journal·May 31

5

Tecentriq and Zepzelca Combo Demonstrates Significant Survival Benefit in Phase III Study for Extensive-Stage Small Cell Lung Cancer

Applied Clinical Trials Online·Jun 3

6

FDA Approves Maintenance Combo for Small Cell Lung Cancer

MedPage Today·Oct 3

7

First-Line Maintenance Lurbinectedin Plus Atezolizumab Boosts Survival in ES-SCLC

OncLive·May 22

8

Zepzelca Plus Tecentriq Significantly Improves Survival in Extensive-Stage Small Cell Lung Cancer

Applied Clinical Trials Online·Oct 15